Alnylam Pharmaceuticals ALNY currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representing a 81% ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid ...

JPMorgan said its survey of 28 physicians treating transthyretin amyloid cardiomyopathy, or ATTR-CM, pointed to steady uptake of BridgeBio’s drug Attruby among newly diagnosed patients and among those ...

BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

Jimmy Addison, a former Clemson University football player and a huge fan, also noticed he was short of breath when walking up the stairs in the stadium during a game.

BridgeBio Pharma is back in focus after its fair value estimate was lifted from $89.79 to $100.05, an increase of about 11% that resets the conversation around upside and risk. That move aligns with ...

By Christy Santhosh March 2 (Reuters) - Intellia Therapeutics said on Monday the U.S. Food and Drug Administration has lifted the clinical hold on a late-stage trial of its gene therapy for a heart ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...

(RTTNews) - BridgeBio Pharma, Inc. (BBIO), a commercial-stage company, reported narrower net loss for the fourth-quarter, while revenue surged from the prior year on improved product revenue. For the ...

Good afternoon. I'll be your conference operator today. [Operator Instructions] Before we begin, I'd like to remind everyone that today's call may contain forward-looking statements within the meaning ...

$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectively ...